Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10263884 | 0.84 | SMYD3 (0.86) | SMYD3NPC1RAB9ALMNAL3MBTL1 | |
| SCHEMBL13559345 | 0.81 | SMYD3 (0.65) | SMYD3NPC1RAB9ALMNAL3MBTL1 | |
| SCHEMBL469009 | 0.81 | SMYD3 (0.70) | SMYD3NPC1RAB9ALMNAL3MBTL1 | |
| SCHEMBL2541108 | 0.81 | SMYD3 (0.66) | SMYD3NPC1RAB9ALMNAL3MBTL1 | |
| SCHEMBL20130636 | 0.80 | SLC7A5 (0.56) | NPC1RAB9ALMNASMN1; SMN2KMT2A | |
| SCHEMBL24529101 | 0.78 | SMYD3 (0.78) | SMYD3NPC1RAB9ALMNAL3MBTL1 | |
| SCHEMBL21257402 | 0.78 | SMYD3 (0.78) | SMYD3NPC1RAB9ALMNAL3MBTL1 | |
| SCHEMBL46936 | 0.78 | FOLH1 (0.59) | RAB9ASMN1; SMN2 | |
| SCHEMBL21489836 | 0.78 | SMYD3 (1.00) | SMYD3NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL14438264 | 0.78 | SMYD3 (0.61) | SMYD3NPC1RAB9ALMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | SMYD3 2656/4885NPC1 3949/4885RAB9A 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.